Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

Breast Cancer Research and Treatment

Volumn 85, Issue 2, 2004, Pages 151-159

  Johnson, Michael D ^a   Zuo, Hong ^a   Lee, Kyung Hoon ^b   Trebley, Joseph P ^c   Rae, James Michael ^d   Weatherman, Ross V ^b   Desta, Zeruesanay ^b   Flockhart, David A ^b   Skaar, Todd C ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PURDUE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Endoxifen; Estrogen receptor; Gene expression; Metabolite; Proliferation; Receptor binding; Tamoxifen

Indexed keywords

4 HYDROXY N NORTAMOXIFEN; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; GENE CONTROL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR BINDING;

BREAST NEOPLASMS; CELL DIVISION; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 3342932419     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000025406.31193.e8     Document Type: Article

References (22)

1. American Cancer Society: Cancer Facts and Figures, 2002
2. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618, 1998
3. Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127-205, 1984
4. Stearns V, Johnson MD, Rae JM et al.: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758-1764, 2003
5. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K: Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51: 73-78, 1996
6. Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M, Clarke R: Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res 54: 441-447, 1994
7. Edwards DP, McGuire WL: 17 alpha-estradiol is a biologically active estrogen in human breast cancer cells in tissue culture. Endocrinology 107: 884-891, 1980
8. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976
9. Johnson MD, Westley BR, May FE: Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br J Cancer 59: 727-738, 1989
10. Jordan VC: Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat 2: 123-138, 1982
11. Patterson JS, Settatree RS, Adam AK, Kemp JV: Serum concentrations of tamoxifen and major metabolites during long-term Nolvadex therapy, correlated with clinical response. In: Mouridsen HT, Palshoff T (eds) Breast Cancer: Experimental and Clinical Aspects. Pergamon Press, Oxford, UK, 1980, p 89
12. Desta Z, Ward BA, Soukhova N, Flockhart DA: Comprehensive kinetic characterization of tamoxifen primary demethylation and hydroxylation by the human cytochrome P450s. Drug Metab Rev 25(Suppl. 2): 189 (abstract #377), 2003
13. Fisher B, Costantino JP, Wickerham DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998
14. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D: Hot flushes. Lancet 360: 1851-1861, 2002
15. Stearns V, Beebe KL, Iyengar M, Dube E: Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289: 2827-2834, 2003
16. Lien EA, Solheim E, Kvinnsland S, Ueland PM: Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48: 2304-2308, 1988
17. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM: Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49: 2175-2183, 1989
18. Shiau AK, Barstad D, Radek JT et al.: Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 9: 359-364, 2002
19. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR: Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 791: 245-253, 2003
20. Marez D, Legrand M, Sabbagh N et al.: Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7: 193-202, 1997
21. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA: Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10: 545-558, 1991
22. Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD: Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics 13: 501-507, 2003